92 related articles for article (PubMed ID: 11928869)
1. Apoptotic bodies as a morphological feature in serous ovarian carcinoma: correlation with nuclear grade, Ki-67 and mitotic indices.
Brustmann H
Pathol Res Pract; 2002; 198(2):85-90. PubMed ID: 11928869
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis and cell proliferation correlated with tumour grade in peritoneal fluids of patients with serous ovarian cancer.
Kalogeraki A; Karvela-Kalogeraki I; Petraki PE; Zois I; Tamiolakis D; Stathopoulos EN
Cytopathology; 2011 Dec; 22(6):383-6. PubMed ID: 20738358
[TBL] [Abstract][Full Text] [Related]
3. Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study.
Brustmann H
Gynecol Oncol; 2004 Jan; 92(1):268-76. PubMed ID: 14751170
[TBL] [Abstract][Full Text] [Related]
4. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
Brustmann H
Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
Brustmann H; Naudé S
Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
8. Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival.
McMenamin ME; O'Neill AJ; Gaffney EF
Mol Pathol; 1997 Oct; 50(5):242-6. PubMed ID: 9497913
[TBL] [Abstract][Full Text] [Related]
9. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival.
Ali-Fehmi R; Morris RT; Bandyopadhyay S; Che M; Schimp V; Malone JM; Munkarah AR
Am J Obstet Gynecol; 2005 Mar; 192(3):819-25. PubMed ID: 15746677
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
11. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
12. Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 proteins in serous ovarian tumors.
Buchynska LG; Nesina IP; Yurchenko NP; Bilyk OO; Grinkevych VN; Svintitsky VS
Exp Oncol; 2007 Mar; 29(1):49-53. PubMed ID: 17431389
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
14. The proliferative activity of ovarian tumors of low malignant potential differs from that of ovarian carcinoma.
Nakayama K; Takebayashi Y; Hata K; Fujiwaki R; Iida K; Fukumoto M; Miyazaki K
Anticancer Res; 2003; 23(6C):4657-62. PubMed ID: 14981910
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic oophorectomy: a morphologic and immunohistochemical study.
Schlosshauer PW; Cohen CJ; Penault-Llorca F; Miranda CR; Bignon YJ; Dauplat J; Deligdisch L
Cancer; 2003 Dec; 98(12):2599-606. PubMed ID: 14669279
[TBL] [Abstract][Full Text] [Related]
16. Architectural patterns of ovarian/pelvic high-grade serous carcinoma.
Bromley AB; Altman AD; Chu P; Nation JG; Nelson GS; Ghatage P; Kalloger SE; Han G; Köbel M
Int J Gynecol Pathol; 2012 Sep; 31(5):397-404. PubMed ID: 22833078
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis.
Brustmann H
Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105
[TBL] [Abstract][Full Text] [Related]
19. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
20. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]